Arrae, Inc.

Midlothian, TX

About Arrae, Inc.

Company overview

Arrae is a Los Angeles-based wellness company that creates targeted natural supplements designed to address everyday health concerns for women using science-backed, plant-based formulations. Co-founded in 2020 by Siffat Haider and Nish Samantray, Arrae seeks to provide effective, holistic remedies for common ailments such as bloating, anxiety, constipation, and fatigue without the use of harsh chemicals or synthetic additives. Product/Service Line Breakdown: 1. Bloat Capsules Purpose: Designed to alleviate bloating and improve digestion. Key Ingredients: Bromelain, ginger root, dandelion root, slippery elm, lemon balm. Use Case: Post-meal discomfort, indigestion, water retention. Form: Capsules. Science-Backed: Formulated with input from naturopathic doctors (Arrae Bloat). 2. Calm Capsules Purpose: Reduces anxiety, stress, and promotes relaxation. Key Ingredients: L-theanine, magnesium bisglycinate, inositol. Use Case: Daytime stress, social anxiety, travel jitters. Form: Capsules. Benefit: Non-drowsy, non-habit forming (Arrae Calm). 3. Sleep Capsules Purpose: Improves sleep onset and quality. Key Ingredients: Chamomile, melatonin, valerian root, L-theanine. Use Case: Insomnia, jet lag, restlessness. Form: Capsules. Unique Aspect: Supports both sleep quality and next-day alertness (Arrae Sleep). 4. Constipation Capsules Purpose: Relieves occasional constipation and supports gut motility. Key Ingredients: Aloe vera, senna leaf, triphala, fennel seed. Use Case: Irregularity, travel constipation, detox support. Form: Capsules. Note: Gentle, natural, and non-habit forming (Arrae Constipation). 5. Heartburn Capsules Purpose: Neutralizes acidity and relieves acid reflux. Key Ingredients: Marshmallow root, licorice root, slippery elm. Use Case: Post-meal acidity, GERD, reflux prevention. Form: Capsules. Formula: Designed for fast and effective acid relief (Arrae Heartburn).

Keywords

Revenue

Revenue

EBITDA

EBITDA

Valuation

Valuation
Income Statement
Line Item20242023202220212020
Revenues$380 MM$250 MM$90 MM$120 MM$65 MM
Gross Profit$190 MM$125 MM$45 MM$60 MM$32.50 MM
Net Income (Loss)$43 MM$25 MM$9 MM$12 MM$6.50 MM
Members Only
Unlock full access to financial data and insights
Balance Sheet
Line Item20242023202220212020
Total Assets$850 MM$720 MM$680 MM$650 MM$600 MM
Total Liabilities$450 MM$400 MM$380 MM$350 MM$320 MM
Total Equity$400 MM$320 MM$300 MM$300 MM$280 MM
Members Only
Unlock full access to financial data and insights

Ratios

Revenue / EBITDA
123 MM
Valuation / Revenue
123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

© 2026 PrivCo Holding Inc. All rights reserved.

No AI Training or Automated Data Extraction.

Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.